Anticoagulant therapy in the management of patients with atrial fibrillation from the viewpoint of comorbidities: focus on choice

Медицинский совет

A. A. Zykova¹  G. F. Piksina²  O. D. Ostroumova²  A. I. Kochetkov²  I. V. Goloborodova² 

[1] Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University);Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia;

关键词: atrial fibrillation;    ischemic heart disease;    diabetes mellitus;    chronic kidney disease;    multimorbidity;    advanced age;    anticoagulant therapy;    apixaban;   

DOI  :  10.21518/2079-701X-2018-5-86-92

来源: DOAJ

【 摘 要 】

The article discusses the choice of anticoagulant therapy in patients with atrial fibrillation and a number of concomitant diseases – coronary heart disease, including after percutaneous coronary interventions, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, and in the elderly. The data of subanalyses of a randomized clinical trial of ARISTOTLE are presented, indicating a high profile of efficacy and safety of the new oral anticoagulant apixaban in this category of patients.

【 授权许可】

Unknown